Trials / Withdrawn
WithdrawnNCT00151385
Study Evaluating Inhibitor Specificity in Hemophilia A
A Multicenter Study to Describe the Immunogenic Epitope(s) of Factor VIII in Previously Treated Patients With Congenital Hemophilia A Who Develop De Novo Factor VIII Inhibitors While Receiving Factor VIII Infusion Therapy.
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This investigation will utilize a systematic determination of anti-FVIII antibody specificity in PTPs (\> 50 ED) with hemophilia A who have developed inhibitors in response to treatment with any FVIII product(s). A group of patients with hemophilia A, who have no evidence of current or prior FVIII inhibitor will be included for comparison. The objective of this study is to describe the patterns of antibodies and associated epitopes in the study population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | single blood draw |
Timeline
- Start date
- 2005-11-01
- Completion
- 2007-10-01
- First posted
- 2005-09-08
- Last updated
- 2012-06-28
Locations
23 sites across 7 countries: United States, Belgium, France, Germany, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00151385. Inclusion in this directory is not an endorsement.